NetSuite Momentum Expected to Continue and 4 Stock Analyses Making the Rounds

BioDelivery Sciences International Inc. (NASDAQ:BDSI): Ladenburg believes that Reckitt Benckiser’s intentions to cease the supply of Suboxone Tablets is positive for BioDelivery Sciences. The firm claims that Reckitt’s plan for the removal of the tablet from the market is not because of any safety issue regarding Suboxone components, and it predicts that this will constrain the ability of generic tablets to gain market share. The firm keeps a Buy rating and a $7.25 price target on the stock.

Universal Display Corp. (NASDAQ:PANL) has entered into an outsourcing manufacturing contract with Korean OLED supplier Duksan Hi-Metal and has mutually agreed that it will dismiss outstanding patent challenges. Goldman believes that the news is positive and comes with long-term positive results. The firm gives the stock a Buy rating.

DepoMed Inc. (NASDAQ:DEPO): According to Roth Capital, the risk/reward of the Depomed lawsuit against the FDA is positive because investor expectations have not resulted in orphan drug exclusivity for Gralise. The firm maintains its Buy rating and a $9 price target on the stock.

NetSuite Inc. (NYSE:N): Goldman’s checks suggest that SaaS ERP adoption has risen along with awareness. The analyst predicts it will see a continued momentum for NetSuite as it believes there will be a longer adoption cycle. Shares have a Conviction Buy rating.

AVG Technologies (NYSE:AVG) estimates have been reduced by Goldman due to slowing PC unit growth. Shares have a Buy rating.